Karyopharm Therapeutics Files 8-K on Financials
Ticker: KPTI · Form: 8-K · Filed: Nov 5, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
TL;DR
Karyopharm dropped an 8-K detailing financial results. Check it for the latest numbers.
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on November 5, 2024, reporting on its results of operations and financial condition. The filing details financial statements and exhibits related to the company's performance. Karyopharm Therapeutics Inc. is incorporated in Delaware and its principal executive offices are located in Newton, Massachusetts.
Why It Matters
This filing provides investors with crucial updates on Karyopharm Therapeutics' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- November 5, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- Newton, Massachusetts (location) — Principal Executive Offices
- 001-36167 (identifier) — SEC File Number
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details of these statements are not enumerated in the provided text.
What is the primary purpose of this 8-K filing for Karyopharm Therapeutics Inc.?
The primary purpose is to report on the company's 'Results of Operations and Financial Condition' and to file 'Financial Statements and Exhibits'.
When was this 8-K report filed?
This 8-K report was filed on November 5, 2024.
Where are Karyopharm Therapeutics Inc.'s principal executive offices located?
Karyopharm Therapeutics Inc.'s principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459.
What is Karyopharm Therapeutics Inc.'s state of incorporation?
Karyopharm Therapeutics Inc. is incorporated in Delaware.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-11-05 07:41:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- d906207d8k.htm (8-K) — 25KB
- d906207dex991.htm (EX-99.1) — 108KB
- g906207g1105071321871.jpg (GRAPHIC) — 4KB
- 0001193125-24-250984.txt ( ) — 274KB
- kpti-20241105.xsd (EX-101.SCH) — 3KB
- kpti-20241105_lab.xml (EX-101.LAB) — 18KB
- kpti-20241105_pre.xml (EX-101.PRE) — 11KB
- d906207d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press release issued by Karyopharm Therapeutics Inc. on November 5, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: November 5, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary